Antimicrobial Shield Technology for Urgent Clinical Need - Medical / Health Care - Clinical Services
Wound infections are on the rise affecting Millions of Americans and costing Billions in healthcare expenditure. According to the Centers for Disease Control and Prevention Report, antibiotic-resistant bacteria will cause serious infections in millions of Americans each year, resulting in patient deaths, morbidity, serious complications, and huge economic losses.
Bacterial colonization is common in wounds (surgical, burn, combat, and chronic) causing impaired tissue regeneration. Every year, complications associated with wound infections result in approximately 500,000 surgical site infections, 100,000 amputations and 99,000 deaths, with a health care burden of 3.7 million excess hospital days, over $428 million hospital re-admission penalties, and over $10 billion in health care expenditure. Patients surviving MRSA (multidrug-resistant Staphylococcus aureus) often spend months in the hospital and endure repeated surgeries to remove the infected tissue. Current treatments include systemic antibiotics, and/or applications of antimicrobial dressings, which are becoming less effective in prevention and treatment of antibiotic-resistant infections, and cause tissue toxicity in regenerating tissue. New prophylactic treatments are needed to prevent bacterial pathogens from wounds through mechanisms against which bacterial resistance will be unlikely to develop, and simultaneously accelerate wound closure.
Wound infections are preventable, Gel4Med has a solution: In order to address the problem of impaired tissue regeneration due to emerging antibiotic resistance associated with wound infections, Gel4Med has developed a new prophylactic technology that prevents bacterial pathogens from wounds through a mechanism of action that makes bacterial resistance unlikely to develop.